A Population-based Study Showing Better Renal Prognosis for Proteinase 3 Antineutrophil Cytoplasmic Antibody (ANCA)-associated Nephritis Versus Myeloperoxidase ANCA-associated Nephritis.

Aladdin Mohammad; Mårten Segelmark

doi:10.3899/jrheum.131038

A Population-based Study Showing Better Renal Prognosis for Proteinase 3 Antineutrophil Cytoplasmic Antibody (ANCA)-associated Nephritis Versus Myeloperoxidase ANCA-associated Nephritis.

Aladdin Mohammad, Mårten Segelmark

Nephrology

Research output: Contribution to journal › Article › peer-review

Abstract

Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is usually differentiated based on clinical phenotypes, but recent data indicate that myeloperoxidase (MPO)-AAV is genetically distinct from proteinase 3 (PR3)-AAV. We reviewed a population-based cohort of AAV, focusing on differences in clinical and laboratory characteristics and to compare renal outcome between MPO-ANCA and PR3-ANCA nephritis.

Original language	English
Pages (from-to)	1366-1373
Journal	Journal of Rheumatology
Volume	41
Issue number	7
DOIs	https://doi.org/10.3899/jrheum.131038
Publication status	Published - 2014

Subject classification (UKÄ)

Rheumatology and Autoimmunity

Access to Document

10.3899/jrheum.131038

http://www.ncbi.nlm.nih.gov/pubmed/24882836?dopt=Abstract

Cite this

@article{c4d6368ad7264c428b62a94865f6f080,

title = "A Population-based Study Showing Better Renal Prognosis for Proteinase 3 Antineutrophil Cytoplasmic Antibody (ANCA)-associated Nephritis Versus Myeloperoxidase ANCA-associated Nephritis.",

abstract = "Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is usually differentiated based on clinical phenotypes, but recent data indicate that myeloperoxidase (MPO)-AAV is genetically distinct from proteinase 3 (PR3)-AAV. We reviewed a population-based cohort of AAV, focusing on differences in clinical and laboratory characteristics and to compare renal outcome between MPO-ANCA and PR3-ANCA nephritis.",

author = "Aladdin Mohammad and M{\aa}rten Segelmark",

year = "2014",

doi = "10.3899/jrheum.131038",

language = "English",

volume = "41",

pages = "1366--1373",

journal = "Journal of Rheumatology",

issn = "0315-162X",

publisher = "Journal of Rheumatology Publishing Company Limited",

number = "7",

}

TY - JOUR

T1 - A Population-based Study Showing Better Renal Prognosis for Proteinase 3 Antineutrophil Cytoplasmic Antibody (ANCA)-associated Nephritis Versus Myeloperoxidase ANCA-associated Nephritis.

AU - Mohammad, Aladdin

AU - Segelmark, Mårten

PY - 2014

Y1 - 2014

N2 - Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is usually differentiated based on clinical phenotypes, but recent data indicate that myeloperoxidase (MPO)-AAV is genetically distinct from proteinase 3 (PR3)-AAV. We reviewed a population-based cohort of AAV, focusing on differences in clinical and laboratory characteristics and to compare renal outcome between MPO-ANCA and PR3-ANCA nephritis.

AB - Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is usually differentiated based on clinical phenotypes, but recent data indicate that myeloperoxidase (MPO)-AAV is genetically distinct from proteinase 3 (PR3)-AAV. We reviewed a population-based cohort of AAV, focusing on differences in clinical and laboratory characteristics and to compare renal outcome between MPO-ANCA and PR3-ANCA nephritis.

U2 - 10.3899/jrheum.131038

DO - 10.3899/jrheum.131038

M3 - Article

C2 - 24882836

SN - 0315-162X

VL - 41

SP - 1366

EP - 1373

JO - Journal of Rheumatology

JF - Journal of Rheumatology

IS - 7

ER -

A Population-based Study Showing Better Renal Prognosis for Proteinase 3 Antineutrophil Cytoplasmic Antibody (ANCA)-associated Nephritis Versus Myeloperoxidase ANCA-associated Nephritis.

Abstract

Subject classification (UKÄ)

Access to Document

Fingerprint

Cite this